Abacus FCF Advisors LLC Has $1.90 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Abacus FCF Advisors LLC grew its position in Hologic, Inc. (NASDAQ:HOLX) by 46.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,340 shares of the medical equipment provider’s stock after acquiring an additional 8,308 shares during the period. Abacus FCF Advisors LLC’s holdings in Hologic were worth $1,899,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of HOLX. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter valued at about $26,000. Venturi Wealth Management LLC increased its holdings in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares in the last quarter. Finally, Smithfield Trust Co boosted its position in Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Up 0.7 %

HOLX stock opened at $61.27 on Tuesday. The company has a market cap of $13.75 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a twelve month low of $59.06 and a twelve month high of $84.67. The business has a 50 day moving average price of $64.07 and a two-hundred day moving average price of $72.37. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research reports. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Citigroup cut their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.